MKI67 and breast carcinoma: Patients with RS < 26 and post-treatment Ki67 ≤ 10% had favorable outcomes with endocrine therapy alone, supporting Ki67 as a marker for chemotherapy omission in certain high-risk luminal breast cancer patients.